Optimata is a member of the Apoptosis Modeling for Treatment Decisions in Colorectal Cancer (APO-DECIDE) consortium, which tackles the problem of chemotherapy resistance in colorectal cancer. By analyzing protein levels and DNA mutations in individual tumors, and by incorporating these biological data into a complex modeling environment that recapitulates how these entities interact, APO-DECIDE develops novel diagnostic tools that predict which patients will likely benefit from chemotherapy. It is a hope that these clinical decision-making tools will enable doctors to develop personalized therapies for patients to ensure the best outcomes while potentially avoiding unnecessary chemotherapy and side effects. These new prediction tools may also be used in clinical trials to develop new drugs to treat bowel cancer, enabling ‘smart’ clinical trials design in the future. Commercialization of the project results will be facilitated by OncoMark Ltd. and Optimata Ltd. The project is supported by the European Union’s Seventh Framework Program (FP7; contract #306021).